Targeting MraY: Synthesis and Validation of MraY Inhibitors
靶向 MraY:MraY 抑制剂的合成和验证
基本信息
- 批准号:8072058
- 负责人:
- 金额:$ 37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-05-15 至 2014-04-30
- 项目状态:已结题
- 来源:
- 关键词:AIDS/HIV problemAcidsAcquired Immunodeficiency SyndromeAmikacinAmino AcidsAmino AlcoholsAnabolismAnti-Bacterial AgentsAnti-HIV AgentsAntibioticsAntimycobacterial AgentsAntitubercular AgentsApplications GrantsBehaviorBiologicalBiological AssayBiological FactorsCapromycinCell LineCellsCessation of lifeCiprofloxacinClinicalCombined Modality TherapyComplexCycloserineCytochrome P450 3A4DepsipeptidesDevelopmentDoseDrug Delivery SystemsDrug KineticsDrug resistance in tuberculosisDrug-sensitiveEnzymesEthambutolEthionamideEvaluationExhibitsFluorescent ProbesFutureGenerationsGenus MycobacteriumGlycopeptidesGoalsGram-Positive BacteriaGrantHIVHIV InfectionsHighly Active Antiretroviral TherapyHospitalsIn VitroIndustryInfectionKanamycinKnowledgeLaboratory ResearchLactamsLeadLibrariesLifeLiver MicrosomesMetabolicModelingMonkeysMulti-Drug ResistanceMultidrug-Resistant TuberculosisMusMycobacterium tuberculosisNucleosidesNucleotidesOfloxacinPatientsPenicillin-Binding ProteinsPeptidoglycanPharmaceutical ChemistryPharmaceutical PreparationsPlasmaPolymersPopulationPositioning AttributePreventionProtease InhibitorPyrazinamideRNA-Directed DNA PolymeraseRelative (related person)ReportingResearchResistanceReverse Transcriptase InhibitorsRifampinRouteSafetyScientistScreening procedureSeriesSolutionsSourceStaphylococcus aureusStreptomycesStructureTimeToxic effectTuberculosisTunicamycinUDP-N-acetylmuramic acid pentapeptideUridineValidationamphomycinanalogantimicrobialbasechemical propertycombatcytotoxicitydesigndrug metabolismefficacy evaluationfunctional groupfungusimprovedin vivoinhibitor/antagonistinterestisoniazidkidney celllipid Imethicillin resistant Staphylococcus aureusmouse modelnovelp-Aminosalicylic Acidprogramspublic health relevanceresistant strainresponsestereochemistrysugartopical antibacterialtreatment strategytuberculosis drugs
项目摘要
DESCRIPTION (provided by applicant): A MraY inhibitor from a natural source, capuramycin, exhibited significant activity in vivo using M. tuberculosis mouse infection model. Muraymycins possess a common core structure of capuramycin, however, their structural diversity is observed in an acyclic complex depsipeptide moiety and the C5'-sugar-appended. Promising in vivo antibactericidal activity of muraymycin A1 against S. aureus was highlighted by the Wyeth-Research groups. Thus, it is of our interest to validate the efficacy of muraymycin A1 in vitro and in vivo against M. tuberculosis. However, the fungus strain (Streptomyces spp. LL-AA896) used to produce muraymycin A1 and any congeners are not available, and muraymycin A1 has to be synthesized for the in vitro compound profiling. Thus, we will establish the synthetic route for intact muraymycin A1 to obtain enough molecules (Specific Aim 1). Furthermore, medicinal chemistry programs of muraymycin A1 and capuramycin with an aim to improve the efficacy including pharmacokinetics are hampered by 1) the complexity of these structures, 2) difficulty in chemically modifying the desired positions selectively, and 3) no convenient assay against Mtb MraY enzyme including difficulty in obtaining enough MraY substrate, Park's nucleotide. We accomplished a scalable chemoenzymatic and total synthesis of Park's nucleotide and its fluorescent probe, and established a convenient MraY inhibitor assay using a cell envelop enriched fraction including MraY, MurG and decaprenylphosphate. In addition, over the past years we obtained extensive knowledge of synthetic accessibility of uridine-amino-alcohol containing molecules in solution or on the polymer- support. We will continue designing and synthesizing new uridine-amino-alcohol derivatives in order to identify the minimal and essential structures of muraymycins and capuramycin (Specific Aim 2). In vitro profiling of the generated molecules against Mtb MraY and drug-sensitive and -resistant M. tuberculosis will be performed at the CSU Mycobacteria Research Laboratory (Specific Aim 3).
PUBLIC HEALTH RELEVANCE: Multidrug resistant Mycobacterium tuberculosis (MDR-TB) has occurred in hospitals and correctional facilities, and frequently in HIV-infected patient. Clinical responses of MDR- TB patient to currently available drugs have been poor, and in some cases there is no response at all. The long term goal of this grant submission is to develop new drug leads for MDR-TB.
描述(由申请人提供):一种天然来源的MraY抑制剂,卡普霉素,在结核分枝杆菌小鼠感染模型中显示出显著的体内活性。muraymycin具有卡普霉素的共同核心结构,然而,它们的结构多样性是在无环复合物沉积肽段和C5'-糖附加部分中观察到的。wyeth研究小组强调了muraymycin A1对金黄色葡萄球菌的体内抗菌活性。因此,验证穆拉霉素A1在体外和体内对结核分枝杆菌的疗效是我们感兴趣的。然而,用于产生muraymycin A1的真菌菌株(Streptomyces spp. l - aa896)和任何同系物都没有,必须合成muraymycin A1进行体外化合物分析。因此,我们将建立完整的muraymycin A1的合成路线,以获得足够的分子(Specific Aim 1)。此外,muraymycin A1和capuramycin的药物化学计划旨在提高包括药代动力学在内的疗效,但这些计划受到以下因素的阻碍:1)这些结构的复杂性;2)难以选择性地对所需位置进行化学修饰;3)无法方便地检测Mtb MraY酶,包括难以获得足够的MraY底物,Park's核苷酸。我们完成了Park's核苷酸及其荧光探针的可扩展化学酶和全合成,并建立了一种方便的MraY抑制剂测定方法,使用富含MraY, MurG和decaprenylphosphate的细胞膜组分。此外,在过去的几年里,我们在含尿苷氨基醇分子在溶液或聚合物载体上的合成可及性方面获得了广泛的知识。我们将继续设计和合成新的尿嘧啶-氨基醇衍生物,以确定鼠霉素和卡普霉素的最小和基本结构(具体目标2)。将在科罗拉多州立大学分枝杆菌研究实验室(Specific Aim 3)对生成的抗Mtb MraY和对药物敏感和耐药的结核分枝杆菌分子进行体外分析。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michio Kurosu其他文献
Michio Kurosu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michio Kurosu', 18)}}的其他基金
Targeting MraY: Synthesis and Validation of MraY Inhibitors
靶向 MraY:MraY 抑制剂的合成和验证
- 批准号:
7986383 - 财政年份:2010
- 资助金额:
$ 37万 - 项目类别:
Targeting MraY: Synthesis and Validation of MraY Inhibitors
靶向 MraY:MraY 抑制剂的合成和验证
- 批准号:
8262701 - 财政年份:2010
- 资助金额:
$ 37万 - 项目类别:
Targeting MraY: Synthesis and Validation of MraY Inhibitors
靶向 MraY:MraY 抑制剂的合成和验证
- 批准号:
8451435 - 财政年份:2010
- 资助金额:
$ 37万 - 项目类别:
相似国自然基金
具有抗癌活性的天然产物金霉酸(Aureolic acids)全合成与选择性构建2-脱氧糖苷键
- 批准号:22007039
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
海洋放线菌来源聚酮类化合物Pteridic acids生物合成机制研究
- 批准号:
- 批准年份:2019
- 资助金额:10.0 万元
- 项目类别:省市级项目
手性Lewis Acids催化的分子内串联1,5-氢迁移/环合反应及其在构建结构多样性手性含氮杂环化合物中的应用
- 批准号:21372217
- 批准年份:2013
- 资助金额:80.0 万元
- 项目类别:面上项目
对空气稳定的新型的有机金属Lewis Acids催化剂制备、表征与应用研究
- 批准号:21172061
- 批准年份:2011
- 资助金额:30.0 万元
- 项目类别:面上项目
钛及含钛Lewis acids促臭氧/过氧化氢体系氧化性能的广普性、高效性及其机制
- 批准号:21176225
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
基于Zip Nucleic Acids引物对高度降解和低拷贝DNA检材的STR分型研究
- 批准号:81072511
- 批准年份:2010
- 资助金额:31.0 万元
- 项目类别:面上项目
海洋天然产物Makaluvic acids 的全合成及其对南海鱼虱存活的影响
- 批准号:30660215
- 批准年份:2006
- 资助金额:21.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Lipid nanoparticle-mediated Inhalation delivery of anti-viral nucleic acids
脂质纳米颗粒介导的抗病毒核酸的吸入递送
- 批准号:
502577 - 财政年份:2024
- 资助金额:
$ 37万 - 项目类别:
CAREER: Highly Rapid and Sensitive Nanomechanoelectrical Detection of Nucleic Acids
职业:高度快速、灵敏的核酸纳米机电检测
- 批准号:
2338857 - 财政年份:2024
- 资助金额:
$ 37万 - 项目类别:
Continuing Grant
Double Incorporation of Non-Canonical Amino Acids in an Animal and its Application for Precise and Independent Optical Control of Two Target Genes
动物体内非规范氨基酸的双重掺入及其在两个靶基因精确独立光学控制中的应用
- 批准号:
BB/Y006380/1 - 财政年份:2024
- 资助金额:
$ 37万 - 项目类别:
Research Grant
Quantifying L-amino acids in Ryugu to constrain the source of L-amino acids in life on Earth
量化 Ryugu 中的 L-氨基酸以限制地球生命中 L-氨基酸的来源
- 批准号:
24K17112 - 财政年份:2024
- 资助金额:
$ 37万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Synthetic analogues based on metabolites of omega-3 fatty acids protect mitochondria in aging hearts
基于 omega-3 脂肪酸代谢物的合成类似物可保护衰老心脏中的线粒体
- 批准号:
477891 - 财政年份:2023
- 资助金额:
$ 37万 - 项目类别:
Operating Grants
Metabolomic profiles of responders and non-responders to an omega-3 fatty acids supplementation.
对 omega-3 脂肪酸补充剂有反应和无反应者的代谢组学特征。
- 批准号:
495594 - 财政年份:2023
- 资助金额:
$ 37万 - 项目类别:
Molecular recognition and enantioselective reaction of amino acids
氨基酸的分子识别和对映选择性反应
- 批准号:
23K04668 - 财政年份:2023
- 资助金额:
$ 37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Integrated understanding and manipulation of hypoxic cellular functions by artificial nucleic acids with hypoxia-accumulating properties
具有缺氧累积特性的人工核酸对缺氧细胞功能的综合理解和操纵
- 批准号:
23H02086 - 财政年份:2023
- 资助金额:
$ 37万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Basic research toward therapeutic strategies for stress-induced chronic pain with non-natural amino acids
非天然氨基酸治疗应激性慢性疼痛策略的基础研究
- 批准号:
23K06918 - 财政年份:2023
- 资助金额:
$ 37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms how arrestins that modulate localization of glucose transporters are phosphorylated in response to amino acids
调节葡萄糖转运蛋白定位的抑制蛋白如何响应氨基酸而被磷酸化的分子机制
- 批准号:
23K05758 - 财政年份:2023
- 资助金额:
$ 37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)